Astellas' peficitinib meets in Phase III for RA

Astellas Pharma Inc. (Tokyo:4503) reported top-line data from the Phase III RAJ3 trial in about 500 patients with rheumatoid arthritis who had an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs)